{"disease":{"id":"neoplasm-rectum","name":"neoplasm rectum"},"drugs":{"marketed":[{"drug_id":"bevacizumab","indication_name":"Malignant neoplasm of colon and/or rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"ramucirumab","indication_name":"Malignant neoplasm of colon and/or rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"avastin","indication_name":"Malignant neoplasm of colon and/or rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"zirabev","indication_name":"Malignant neoplasm of colon and/or rectum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04281667","title":"Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":604,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT04534075","title":"Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT05728710","title":"Outcomes of Perforation After Colorectal Endoscopic Submucosal Dissection","phase":"","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03287843","title":"Appropriate Timing of Surgery After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Ege University","has_results":true},{"nct_id":"NCT03211715","title":"Validation of Low Anterior Resection Syndrome Score in Korean Version","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Saint Vincent's Hospital, Korea","has_results":false},{"nct_id":"NCT03573791","title":"Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":152,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05411783","title":"Low Tie Versus High Tie of the Inferior Mesenteric Vein During Colorectal Cancer Surgery: A Randomized Clinical Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":84,"lead_sponsor_name":"San Carlo di Nancy Hospital","has_results":false},{"nct_id":"NCT03198338","title":"Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit","phase":"NA","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT02425683","title":"Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"US Oncology Research","has_results":false},{"nct_id":"NCT02641691","title":"Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Washington University School of Medicine","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}